OmniBuds AI is redefining the future of Remote Patient Monitoring (RPM) through the world's first in-ear clinical-grade health device that doubles as premium earbuds. Addressing a $175B RPM market and leveraging global earbud shipments of 600M+ annually, OmniBuds offers continuous, cuffless monitoring of blood pressure, heart rate, respiration, and more, seamlessly integrated into daily life.
Our Gen I device has been built with proprietary multi-modal sensing including 11 patents, OmniBuds is designed for high patient adherence, regulatory-grade accuracy, and full compatibility with RPM reimbursement codes. Early trials show accuracy exceeding industry benchmarks (SBP 86%, DBP 90%) and strong user engagement, especially in hypertension use cases, which is the world's leading killer with 1.3BN people sufferers.
OmniBuds operates a multi-channel business model: device sales, SaaS, and RPM reimbursement, unlocking scalable, recurring revenue across B2B, OEM, and provider networks. With just two US Healthcare Providers, OmniBuds could generate over $1B in annual RPM reimbursements.
Led by business and technical/scientific experts from Nokia Bell Labs, The University of Cambridge, and B-Secur, the company is seeking £4M to complete clinical validation, commence regulatory approvals, and launch its Gen II solution via key RPM partners.
The goal: a £50M+ run rate by 2029, driven by enterprise adoption, value-based care, and a new generation of hybrid devices that deliver medical-grade health monitoring through earbuds people already use for music, calls, and daily life, making proactive care truly seamless.